QIAGEN and CENTOGENE to collaborate in bioinformatics for genetic diseases

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases

11-Oct-2017 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing ...

QIAGEN and Biotype Diagnostics form partnership

30-Jun-2015 - QIAGEN and Biotype Diagnostics GmbH announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation"). The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s ...

QIAGEN announces broad agreement with Astellas Pharma to develop companion diagnostics

First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development

30-Oct-2014 - QIAGEN N.V. announced a master collaboration agreement with Astellas Pharma Inc. to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or ...

QIAGEN announces third co-development program for companion diagnostics paired with Lilly’s investigational cancer compounds

21-Nov-2013 - QIAGEN announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic ...

QIAGEN achieves Personalized Healthcare milestone with U.S. approval of companion diagnostic for colorectal cancer

11-Jul-2012 - QIAGEN N.V. announced it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer. The U.S. FDA approval of ...

QIAGEN to develop new companion diagnostic for compound in clinical trials for blood cancers

Lilly will co-develop companion diagnostic

08-Sep-2011 - QIAGEN announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were ...

QIAGEN and Pfizer partner to develop companion diagnostic for novel compound in global clinical trials for lung cancer

18-Aug-2011 - QIAGEN announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer (NSCLC). Financial terms of the agreement ...

QIAGEN makes proposal to fully acquire Ipsogen

16-Jun-2011 - QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blood) ...

QIAGEN makes proposal to acquire Australian diagnostics company Cellestis Limited

04-Apr-2011 - QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million (US$355 million) in cash, providing QIAGEN with access to a novel “pre-molecular” technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.The ...

QIAGEN and Roche settle dispute over distribution agreement for TheraScreen companion diagnostics

28-May-2010 - QIAGEN N.V. announced that it has signed an agreement with Roche Molecular Systems Inc., a unit of Roche Holding AG, resolving a dispute over distribution rights for a set of companion diagnostic products developed and manufactured by QIAGEN’s Manchester subsidiary DxS Ltd. Subsequently, the ...